Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma

Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma

Background The potential therapeutic efficacy of daratumumab in natural killer T-cell lymphoma (NKTL) was highlighted when its off-label usage produced sustained remission in a patient with highly refractory disease. This is corroborated recently by a phase II clinical trial which established that d...

Full description

Bibliographic Details
Main Authors: Jennifer Yang, Anand D Jeyasekharan, Joanne Lee, Wee Joo Chng, Tae-Hoon Chung, Nurulhuda Mustafa, Adina Huey Fang Nee, Jing Yuan Chooi, Sabrina Hui Min Toh, Viknesvaran Selvarajan, Shuangyi Fan, Siok Bian Ng, Michelle Poon, Esther Chan, Yen Lin Chee, Longen Zhou
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/7/e002123.full

Internet

https://jitc.bmj.com/content/9/7/e002123.full

Similar Items